Sun Pharmaceutical Industries Ltd: History, Latest Updates, Milestones, Subsidiaries & Share Price

INTRODUCTION

Sun Pharmaceutical Industries Ltd. (Sun Pharma) stands as the fourth largest specialty generic pharmaceutical company worldwide, boasting global revenues amounting to US$ 5.4 billion. Supported by 43 manufacturing facilities, we offer high-quality, affordable medicines trusted by healthcare professionals and patients across more than 100 countries. 

Sun Pharma caters to diverse healthcare needs across six continents, including Asia, North America, Europe, Africa, South America, and Australia. An impressive 68% of the company’s total turnover originates from its extensive export operations. Operating more than 40 manufacturing facilities globally underscores Sun Pharma's commitment to ensuring a consistent and reliable supply of medications to numerous individuals worldwide.

Sun Pharmaceutical Industries Ltd. MOVES IN 2024:

Sun Pharmaceutical Industries Limited released its financial report for the quarter ending December 31st, 2023. Here are the key highlights from the consolidated financials for Q3FY24:

• Gross sales amounted to Rs. 121,569 million, showing a growth of 9.5%,influencing sun pharma share price.

• Sales from India formulations reached Rs. 37,785 million, marking an increase of 11.4%.

• US formulation sales totaled US$ 477 million, reflecting a growth of 13.2%. Sun Pharma share price experienced stability amid these positive results.

• Global specialty sales stood at US$ 296 million, including a US$ 20 million milestone received in Q3, showing a growth of 24.2% excluding milestones and impacting sun pharma share price.

• Research and Development (R&D) investments amounted to Rs. 8,245 million, compared to Rs. 6,702 million in Q3FY23.

• The distinctive EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) amounted to Rs. 34,768 million (including other operating revenues), marking a growth of 15.8%. The EBITDA margin for Q3 was 28.1%, compared to 26.7% in Q3FY23 impacting sun pharma share price tremendously.

• The unique adjusted net profit (excluding exceptional items) for Q3FY24 was Rs.25,936 million, marking an increase of 19.7%. Reported net profit for Q3FY24 was Rs. 25,238 million compared to Rs. 21,660 million during Q3FY23,affecting sun pharma share price.

Evolution of Sun Pharmaceutical Industries Ltd.: From Past to Present:

• 1983: Sun Pharmaceutical Industries Ltd. was established with a primary focus on psychiatry products. Starting with just five products and a small marketing team, the company set its roots in Vadodara, India, by establishing its first manufacturing facility for tablets and capsules.

• 1988: The company expanded its product portfolio by launching its first cardiology products, Mantra and Ang. This expansion allowed Sun Pharma to diversify its product range and make a meaningful impact in another crucial area by establishing a footprint in the cardiology segment.

• 1992: Sun Pharma made its first foray into the international market.

• 1994: Sun Pharma made its debut on the public stock exchange, marking a significant milestone in its journey.

• 1997: Sun Pharma ventured into international acquisitions by acquiring Caraco Pharmaceutical Laboratories in the USA.

• 2000: The acquisition of Propharma in India contributed to expanding Sun Pharma's product portfolio.

• 2004: Sun Pharma established its first joint venture manufacturing unit in Dhaka and acquired Picopain and niche brands from MJ Pharma in the USA.

• 2005: Sun Pharma further expanded its manufacturing capabilities by acquiring a manufacturing unit in Bryan, Ohio, USA, and acquired ICN's operations in Hungary from Valeant Pharma, enhancing its global footprint.

• 2010: Sun Pharma gained control of a significant stake in Taro Pharmaceuticals, headquartered in the USA, leading to a significant increase in the company's business in the United States.

• 2012: Sun Pharma acquired DUSA Pharmaceuticals and the generic business of URL Pharma in the USA.

• 2014: Sun Pharma made a significant acquisition by purchasing Ranbaxy for US$4 billion, becoming the world's fifth-largest specialty generic pharmaceutical company. Additionally, it acquired Pharmalucence in the USA.

• 2015: Sun Pharma acquired GSK's OTC business in Australia.

• 2019: Sun Pharma launched the specialty product Cequa in the United States for dry eye treatment.

• 2021: Sun Pharma entered the nutrition bar market in India by introducing Revital NXT to the market.

• 2022: The company expanded its global reach by acquiring the active pharmaceutical ingredient portfolio from Teva Pharma in Romania.
  

Timeline of Sun Pharmaceutical Industries Ltd.:

Inside Sun Pharmaceutical Industries Ltd.: Exploring Subsidiary Ventures 

Sun Pharmaceutical Industries Ltd.

Corporate actions: On February 9, 2024, an interim dividend of 8.50 was declared for equity shares, with the ex-date and record date being the same.

Main News: Sun Pharma is set to acquire a 16.33% stake in the U.S. firm Surgimatix for $3.05 million.

Main News: On January 31, 2024, Sun Pharmaceutical Industries Ltd. announced a 16.52% increase in its third-quarter consolidated net profit, reaching Rs. 2,524 crore compared to Rs. 2,166 crore In the corresponding period from the previous year. Gross sales also experienced a 9.5% growth, reaching Rs. 12,157 crore. Specifically, India formulation sales rose by 11.4% to Rs. 3,778.5 crore, and U.S. formulation sales increased by 13.2% to $477 million.

TARO Pharmaceuticals

Main News: Taro has announced a merger with Sun Pharma in a deal worth Rs. 2,892 crore. Once the merger is finalized, anticipated to occur in the first half of 2024, Taro will transition into a privately held entity, and its shares will cease trading on the NYSE.

 Sun Pharmaceutical Industries Ltd. share price NSE Today:

Achievements and milestones:

CONCLUSION

Sun Pharma remains steadfast in its commitment to improving global health. From its inception, Sun Pharmaceutical has prioritized providing high-quality medication at affordable prices, ensuring accessibility for all. With a rich history marked by growth and innovation, the company continuously solidifies its global presence, positioning itself as a leader in the pharmaceutical industry. Its diverse product portfolio and dedicated team underscore its unwavering dedication to promoting health and well-being. Additionally, the company keeps a close eye on market dynamics, ensuring transparency and efficiency in its operations, which in turn positively impact Sun Pharma share price.

Enrich Money offers investors the opportunity to invest in Sun Pharma stocks with ease, providing a free demat and trading account for seamless trading experience and financial growth.

Frequently Asked Questions:

 

Where can I find the sun pharma share price today?

To check the sun pharma share price today, please visit the sun pharma share price today on Enrich Money page 

What is the current market cap of sun pharma? 

The Market Capitalization of the sun pharmaceutical industries share price today is Rs. 3.71 trillion.

What has been the highest sun pharmaceutical industries ltd share price in the last 52 weeks?

52 Week's highest of sun pharmaceutical industries ltd share price is Rs1,072.15, while 52 week's low is Rs 789.90

What is the sun pharma share price value?

sun pharma share price/face value is Rs. 1

What factors influence Sun Pharma share price?

Several factors can influence Sun Pharma share price, including company performance, market sentiment, industry trends, regulatory changes, and macroeconomic factors.

How can I analyze Sun Pharma share price trends?

You can analyze Sun Pharma share price trends using technical analysis tools of ORCA APP.

Disclaimer: This blog is dedicated exclusively for educational purposes. Please note that the securities and investments mentioned here are provided for informative purposes only and should not be construed as recommendations. Kindly ensure thorough research prior to making any investment decisions. Participation in the securities market carries inherent risks, and it's important to carefully review all associated documents before committing to investments. Please be aware that the attainment of investment objectives is not guaranteed. It's important to note that the past performance of securities and instruments does not reliably predict future performance.